Live
- DEO suspends teacher accused of sexual assault
- PM ‘cursing’ Congress out of despair: Maharashtra Cong Chief
- Applications are invited for Junior Colleges Scheme District Scheduled Castes Development Officer Ramlal
- A nomination was filed on the second day for the Nagar Kurnool parliamentary seat
- SP Gaikwad inspected the Telangana Amarnath Saleswaram Jatara yatra arrangements
- Rahul Gandhi's decision to contest from Wayanad shows 'lack of confidence': BJP President Nadda
- IPL 2024: Delhi bowlers will go after all of SRH’s top-order batters, says head coach Ricky Ponting
- At Amroha rally, PM Modi sends out ‘meaningful’ message for Muslims and Hindus
- Tripura records highest 79.83 pc voter turnout in Northeast
- The government has to clear the confusion
Zydus gets final approval from USFDA for Lacosamide injection
Zydus gets final approval from USFDA for Lacosamide injection
Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to market its generic Lacosamide injection, which is used to treat partial-onset seizures.The approval granted by the US Food and Drug Administration USFDA is for Lacosamide injection of strength 200 mg20 ml 10 mgml single-dose vials, the company said in a regulatory filing.The drug will be manufactured at the groups injectables manufacturing facility at Jarod, Gujarat, it added.
Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to market its generic Lacosamide injection, which is used to treat partial-onset seizures.
The approval granted by the US Food and Drug Administration (USFDA) is for Lacosamide injection of strength 200 mg/20 ml (10 mg/ml) single-dose vials, the company said in a regulatory filing.
The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat, it added. Lacosamide injection is used to treat partial-onset seizures. It is also used with other medicines to treat primary generalised tonic-clonic seizures. It acts on the Central Nervous System (CNS) to reduce the number and severity of seizures, the company said. Citing IQVIA MAT May 22 data, Zydus said Lacosamide injection has a market size of USD 50 million.
The group now has 316 approvals and has so far filed over 420 abbreviated new drug applications since the commencement of the filing process in FY 2003-04, it said.
